CURRICULUM VITAE

HEFEI WEN

NOVEMBER 2021

CONTACT INFORMATION

Harvard Medical School & Harvard Pilgrim Health Care Institute
Department of Population Medicine, Division of Health Policy & Insurance Research
401 Park Drive, Suite 401 East
Boston MA 02215
Phone: (617) 867-4926
Email: hefei_wen@hphci.harvard.edu

ACADEMIC APPOINTMENTS

2021~Present	Assistant Professor of Population Medicine, Harvard Medical School
2019~Present	Faculty Member, Department of Population Medicine, Harvard Pilgrim Health Care Institute
2015~2019	Assistant Professor, Department of Health Management & Policy, University of Kentucky College of Public Health

EDUCATION

2015	Ph.D., Health Services Research & Health Policy, Emory University
2008	B.A., *magna cum laude*, Economics, Peking University

HONORS & AWARDS

2020	Harvard Medical School Eleanor & Miles Shore Faculty Award
2020	Best of *AcademyHealth* Annual Research Meeting
2018	AUPHA John D. Thompson Prize
2018	Best of *AcademyHealth* Annual Research Meeting
2017	Delta Omega Honorary Public Health Society
2015	Best of *AcademyHealth* Annual Research Meeting

PUBLICATIONS

PEER-REVIEWED JOURNAL ARTICLES

1. KJ Johnston, **H Wen**, HA Pollack. (2021). "A Comparison of Ambulatory Care Access and Quality for Beneficiaries with Disabilities Covered by Medicare Advantage vs Traditional Medicare Insurance." ***JAMA Health Forum***. In Print.
2. KJ Johnston, **H Wen**, KE Joynt Maddox, HA Pollack. (2021). "Ambulatory Care Access and Emergency Department Use for Medicare Beneficiaries with and without Disabilities." ***Health Affairs***. 40(6): 910-919.
3. JC Maclean, **H Wen**, K Simon, B Saloner. (2021). "Institutions for Mental Disease Waivers: Impact on Payments for Substance Use Treatment Facilities." ***Health Affairs***. 40(2): 326-333.
4. J Wen, ***H Wen**, JS Butler, JC Talbert. (2021) "Impact of Medical and Recreational Marijuana Laws on Opioid Prescribing in Employer-Sponsored Health Insurance." ***Health Economics***. 30(5): 989-1000.
   * Corresponding author, student first author
5. C Drake, J Wen, J Hinde, ***H Wen**. (2021) "Impact of Medical and Recreational Marijuana Laws on Opioid Prescribing in Employer-Sponsored Health Insurance." ***Health Economics***. 30(10): 2595-2605.
   * Senior author
6. KJ Johnston, **H Wen**, A Kotwal, KE Joynt Maddox. (2021). "Comparing Preventable Acute Care Use of Rural Versus Urban Americans: An Observational Study of National Rates During 2008-2017." ***Journal of General Internal Medicine***. 36(12):3728-3736.
7. X Ji, JR Cummings, AC Mertens, **H Wen**, KE Effinger. (2021). "Substance Use, Substance Use Disorders, and Treatment in Adolescent and Young Adult Cancer Survivors: Results from a National Survey." ***Cancer***. 127(17): 3223-3231.
   - ❖ *Editorial Commentary*
8. **H Wen**, A Soni, A Hollingsworth, S Freedman, JA Benitez, K Simon, B Saloner. (2020). "Association between Medicaid Expansion and Rates of Opioid-Related Hospital Use." ***JAMA Internal Medicine***. 180(5): 753-759.
   - ❖ Featured in *Kaiser Health News*
9. **H Wen**, BG Druss, B Saloner. (2020). "Self-Help Groups and Medication Use in Opioid Addiction Treatment: A National Analysis." ***Health Affairs***. 39(5): 740-746.
   - ❖ *Editorial Commentary*, *Health Affairs Blog*
   - ❖ Featured in *Kaiser Health News*
10. **H Wen**, ML Barnett, B Saloner. (2020). "Clinical Risk Factors for COVID-19 Among People with Substance Use Disorders." ***Psychiatric Services***. 71(12): 1308-1308.
11. KJ Johnston, **H Wen**, KE Joynt Maddox. (2020). "Inadequate Risk Adjustment Impacts Geriatricians' Performance on Medicare Cost and Quality Measures." ***Journal of the American Geriatrics Society***. 68(2): 297-304.
    - ❖ *Editorial Commentary*

12. KJ Johnston, **H Wen**, KE Joynt Maddox. (2020). "Relationship of a Claims-Based Frailty Index to Annualized Medicare Costs: A Cohort Study." ***Annals of Internal Medicine***. 172(8): 533-540.
    - *Editorial Commentary*
    - Awarded "Best of *AcademyHealth* 2020 Annual Research Meeting"
13. E Golberstein, **H Wen**, BF Miller. (2020). "Coronavirus Disease 2019 (COVID-19) and Mental Health for Children and Adolescents." ***JAMA Pediatrics***. 174(9): 819-820.
    - Featured in *Washington Post*, *CNN*, *BBC*, *ABC*, *Forbes*
14. H Zhang, S Tallavajhala, SN Kapadia, PJ Jeng, Y Shi, **H Wen**, Y Bao. (2020). "State Opioid Limits and Volume of Opioid Prescriptions Received by Medicaid Patients." ***Medical Care***. 58(12): 1111-1115.
15. **H Wen**, JM Hockenberry, PJ Jeng, Y Bao. (2019). "Prescription Drug Monitoring Program Mandates: Impact on Opioid Prescribing and Related Hospital Use in Medicaid." ***Health Affairs***. 38(9): 1550-1556.
16. **H Wen**, KJ Johnston, L Allen, TM Waters. (2019). "Medicaid Expansion Associated with Reductions in Preventable Hospitalizations." ***Health Affairs***. 38(11): 1845-1849.
    - Awarded "Best of *AcademyHealth* 2018 Annual Research Meeting"
    - Feature in *Forbes*
    - Cited in *The National Academies of Sciences, Engineering, & Medicine* "Leading Health Indicators 2030: Advancing Health, Equity, and Well-Being."
17. **H Wen**, B Saloner, JR Cummings. (2019). "Behavioral and Other Chronic Health Conditions Among Adult Medicaid Enrollees: Implications for Work Requirements." ***Health Affairs***. 38(4): 660-667.
    - Featured in *Reuters*
18. **H Wen,** TF Borders, JR Cummings. (2019). "Trends in Buprenorphine Prescriptions by Physician Specialty." ***Health Affairs***. 38(1): 24-28.
    - *Editorial Commentary*
19. **H Wen**, AS Wilk, BG Druss, JR Cummings. (2019). "Medicaid Acceptance by Psychiatrists Before and After Medicaid Expansion." ***JAMA Psychiatry***. 76(9): 981-983.
    - Featured in *Reuters*, *Kaiser Health News*
20. **H Wen**, JM Hockenberry, BG Druss. (2019). "The Effect of Medical Marijuana Laws on Marijuana-Related Attitude and Perception among US Adolescents and Young Adults." ***Prevention Science***. 20(2):215-223. Invited Special Issue Submission.
    - *Editorial Commentary*
21. KJ Johnston, **H Wen**, KE Joynt Maddox. (2019). "Why Do Rural Medicare Beneficiaries with Complex Chronic Conditions Have Higher Rates of Preventable Hospitalization and Mortality than Urban Beneficiaries?" ***Health Affairs***. 38(12): 1993-2002.
22. KJ Johnston, **H Wen,** M Schootman, KE Joynt Maddox. (2019). "Association of Patient Social, Cognitive, and Functional Risk Factors with Preventable Hospitalizations: Implications for Physician Value-Based Payment." ***Journal of General Internal Medicine***. 34(8): 1645-1652.

23. **H Wen**, JM Hockenberry. (2018). "Association of Medical and Adult-Use Marijuana Laws with Opioid Prescribing for Medicaid Enrollees." ***JAMA Internal Medicine***. 178(5): 673-679.
    - *Editorial Commentary*, 5th most talked about *JAMA Intern Med* article in 2018.
    - Featured in *Washington Post*, *NPR*, *CNN*, *NBC*, *CBS*, *Forbes*, *Rolling Stone*, *The Guardian*
24. **H Wen**, JM Hockenberry, HA Pollack. (2018). "Association of Buprenorphine-Waivered Physician Supply with Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees." ***JAMA Network Open***. 1(5):e182943.
25. KJ Johnston, **H Wen**, JM Hockenberry, KE Joynt Maddox. (2018). "Association between Patient Cognitive and Functional Status and Medicare Total Annual Cost of Care: Implications for Value-Based Payment." ***JAMA Internal Medicine***. 178(11):1489-1497.
    - *Editorial Commentary*
26. **H Wen**, BR Schackman, B Aden, Y Bao. (2017). "States with Prescription Drug Monitoring Mandates Saw a Reduction of Opioids Prescribed to Medicaid Enrollees." ***Health Affairs***. 36(4): 733-741.
    - Featured in *New York Times*, *Bloomberg Editorials*
    - Cited in *The National Academies of Sciences, Engineering, & Medicine* "Pain Management and the Opioid Epidemic."
27. **H Wen**, JM Hockenberry, JR Cummings. (2017). "Effect of Medicaid Expansion on Crime Reduction: Evidence from HIFA-Waiver Expansions." ***Journal of Public Economics***. 154: 67-94.
    - Featured in *MSNBC*, *NBER Bulletin*
28. **H Wen**, JM Hockenberry, TF Borders, BG Druss. (2017). "Impact of Medicaid Expansion on Medicaid-Covered Utilization of Buprenorphine for Opioid Use Disorder Treatment." ***Medical Care***. 55(4): 336-341.
    - Featured in *The Economist*
    - Cited in *The National Academies of Sciences, Engineering, & Medicine* "Medications for Opioid Use Disorder Save Lives."
29. **H Wen**, TF Borders, BG Druss. (2016). "Number of Medicaid Prescriptions Grew and Spending Was Steady in Medicaid Expansion States." ***Health Affairs***. 35(9): 1604-1607.
30. JR Cummings, **H Wen**, M Ko. (2016). "Decline in Public Substance Use Disorder Treatment Centers Most Serious in Counties with High Shares of Black Residents." ***Health Affairs***. 35(6): 1036-1044.
31. **H Wen**, JM Hockenberry, JR Cummings. (2015). "The Effect of Medical Marijuana Laws on Adolescent and Adult Use of Marijuana, Alcohol, and Other Substances." ***Journal of Health Economics***. 42: 64-80.
    - Top 10 most downloaded *JHE* article in 2015.
    - Featured in *The Economist*, *PBS NewsHour*, *Vox*, *NBER Digest*
32. **H Wen**, BG Druss, JR Cummings. (2015). "Effect of Medicaid Expansions on Health Coverage and Access to Care among Low-Income Adults with Behavioral Health Conditions." ***Health Services Research***. 50(6): 1787-1809.
    - Awarded "Best of *AcademyHealth* 2015 Annual Research Meeting"
    - Cited in *The White House* "Making Health Care Better" Series on Mental Health
      The Surgeon General's Report "Facing Addiction in America."

HHS Report "Benefits of Medicaid Expansion for Behavioral Health."

33. JR Cummings, **H Wen**, A Ritvo, BG Druss. (2014). "Health Insurance Coverage and Receipt of Specialty Treatment for Substance Use Disorders among U.S. Adults." ***Psychiatric Services***. 65(8): 1070-1073.
34. JR Cummings, **H Wen**, M Ko, BG Druss. (2014). "Race/Ethnicity and Geographic Access to Medicaid Substance Use Disorder Treatment Facilities in the United States." ***JAMA Psychiatry***. 71(2): 190-196.
35. **H Wen**, JR Cummings, JM Hockenberry, LM Gaydos, BG Druss. (2013). "State Parity Laws and Access to Treatment for Substance Use Disorder in the United States: Implications for Federal Parity Legislation." ***JAMA Psychiatry***. 70(12): 1355-1362.
    - ❖ Cited in *The White House* Mental Health & Substance Use Disorder Parity Task Force Report *HHS Report* "Continuing Progress on the Opioid Epidemic: The Role of Affordable Care Act." *The National Academies of Sciences, Engineering, & Medicine* "Psychosocial Interventions for Mental and Substance Use Disorders."
36. JR Cummings, **H Wen**, BG Druss. (2013). "Improving Access to Mental Health Services for Youth in the United States." ***JAMA***. 309(6):553-554.
37. JR Cummings, **H Wen**, M Ko, BG Druss. (2013). "Geography and Medicaid Mental Health Care Infrastructure." ***JAMA Psychiatry***. 70(10): 1084-1090.
38. JR Cummings, **H Wen**, BG Druss. (2011). "Racial/Ethnic Differences in Treatment for Substance Use Disorders among U.S. Adolescents." ***Journal of the American Academy of Child & Adolescent Psychiatry***. 50(12): 1265-1274.

Book Chapters

H Wen, P Hung, X Ji, S Li. "China's Health System." in BJ Fried & LM Gaydos eds. ***World Health System: Challenges and Perspective***. Health Administration Press, 2012.

GRANT FUNDING

CURRENT FUNDING

2020~2021: ***Impact of Opioid Prescribing Policies for Pain Management in Medicare.***
Funded by *Harvard Medical School & Harvard Pilgrim Health Care Institute Faculty Grant*
Principal Investigator

- This project will generate timely knowledge about whether the state prescription limit laws and Medicare opioid safety edits have alleviated excessive opioid prescribing, while ensuring appropriate pain management in the elderly Medicare population.

2021: ***Racial Disparities in Opioid Tapering and the Impact of State Opioid Policies.***
Funded by *Harvard Medical School & Harvard Pilgrim Health Care Institute Faculty Grant*
Principal Investigator

- This project will elucidate the differences in appropriate and inappropriate opioid tapers between White, Black, and Hispanic commercial plan enrollees who are prescribed long-term opioid therapy and the opioid-related state policy effects on racial/ethnic disparities.

2021~2025: ***Can the Medicare Quality Payment Program Incentivize Evidence-Based Treatment of Depression and Anxiety Disorders by Primary Care Providers?***
Funded by *National Institute of Mental Health* (R01MH125820)
Co-Investigator (PI: Kenton J. Johnston): 2021: 3%; 2022~2025: 30%

- This project will evaluate the effect of Quality Payment Program financial incentives on access to, and outcome of, evidence-based treatment by primary care physicians for depression and anxiety disorders.

2020~2021: ***State-level Barriers and Facilitators for Evidence-Based Treatment of Opioid Use Disorder Among the Uninsured Population.***
Funded by *Laura & John Arnold Foundation*
Co-Investigator (PI: Richard Grucza): 2021: 5%

- This project uses qualitative, semi-quantitative and quantitative methods to examine state policies and practices governing opioid use disorder treatment for uninsured individuals.

2020~2022: ***RECOVER: Understanding COVID-19 Impacts on Health Outcomes and Equity in the New England Region.***
Funded by *Harvard Pilgrim Health Care Institute*
Co-Investigator (MPIs: J. Frank Wharam, Alison A. Galbraith): 2021~2022: 2%

- The project seeks to determine the impact of the COVID-19 pandemic on commercial health insurance enrollment, health services utilization, and health outcomes among Harvard Pilgrim Health Care members.

2021~2024: ***Promoting Health by Understanding Risk and Protective Factors for Substance Use among Latino Youth in Rural and Small-Town Communities in the U.S.***
Funded by *National Institute on Drug Abuse* (R01DA048827)
External Consultant (PI: Katarina Guttmannova)

- This project capitalizes on existing rich community based longitudinal data and applies a prevention science paradigm to examine health disparities in substance use and factors influencing the health and well-being of a marginalized population residing in rural U.S.

Previous Funding

2016~2020: ***Center for Rural Health Research.***
Funded by *Health Resources and Services Administration* (U01CRH30041)

Co-Investigator (PI: Tyrone F. Borders): 2016~2019: 15%

- This project aims to examine the effects of Medicaid expansion on insurance coverage and access to substance abuse treatment and the rural-urban differences in policy effects.

2015~2016: ***Prescription Drug Monitoring Programs and Opioid Prescribing.***
Funded by *Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH) Research Grant*

External Consultant (PI: Yuhua Bao)

- This project aims to assess the impact of implementation and mandatory use of prescription drug monitoring programs on opioid prescribing and related outcomes.

Pending Funding

2021~2025: ***Impact of Medicare Part D Opioid Safety Policies on Disabled Beneficiaries Before and During the COVID-19 Pandemic***
Funded by *National Institute on Drug Abuse* (R01DA055131)

Principal Investigator

- This project will examine beneficial and detrimental effects of Medicare opioid safety edits policy implementation on disabled beneficiaries who are prescribed long-term opioid therapy and compare the racial/ethnic and rural-urban differences in beneficial and detrimental policy effects.

2021~2025: ***Impact of High Deductible Health Plans and COVID-19 on Alcohol Use Disorder Treatment Access, Outcomes, and Disparities?***
Funded by *National Institute on Alcohol Abuse and Alcoholism* (R01AA029819)

Co-Investigator/Project Leader (PI: J. Frank Wharam)

- This project seeks to examine the impact of high-deductible health plans and the COVID-19 pandemic on alcohol use disorder treatment access, outcomes, and disparities.

SELECTED CONFERENCE PRESENTATIONS

AcademyHealth Annual Research Meeting:

2020: "Adding a Claims-Based Frailty Index to Medicare's Risk Adjustment Model Can Improve Prediction of Annual Medicare Costs and Enable Equitable Reimbursement."

2018: "The Impact of Medicaid Expansion on Preventable Hospitalizations and Spending."

2016: "Prescription Drug Monitoring Program Mandates Associated with Reduced Opioid Use by Medicaid Enrollees."

2015: "Effect of Medicaid Expansions for Low-Income Adults on Health Coverage for and Access to Mental Health Care."

2013: "Medicaid Expansion, Substance Abuse Treatment Use, and Crime Reduction."

American Society of Health Economists (ASHEcon) Biennial Conference:

2016: "Estimating the Implications of Medication-Assisted Treatment for Opioid Use."

2014: "Fighting Crime through Treatment: Evidence from Public Insurance Expansions and Health Insurance Parity Mandates for Substance Abuse Treatment."

SERVICES

AD-HOC REVIEWER

Addiction
Health Affairs
Health Economics
Health Services Research
JAMA, JAMA Internal Medicine, JAMA Pediatrics, JAMA Psychiatry
Journal of Health Economics

TEACHING & MENTORSHIP

COURSE INSTRUCTOR

2016~2019 *"**Health Economics**."* University of Kentucky
2017~2018 *"**Doctoral Seminar in Research Methods**."* University of Kentucky (Co-Instructor)
2014 *"**Advanced Quantitative Methods I**."* Emory University (Co-Instructor)

DOCTORAL ADVISOR

D. Keith Branham, University of Kentucky College of Public Health, Dr.Ph.
Research Analyst, Center for Medicaid and CHIP Services

Lava Timsina, University of Kentucky College of Public Health, Ph.D.
Assistant Professor of Surgery, Indiana University School of Medicine

Katherine Toran, University of Kentucky Gatton College of Business and Economics, Ph.D.
Economist, Food and Drug Administration Office of Policy, Legislation, International Affairs

Jiebing Wen, University of Kentucky Martin School of Public Policy & Administration, Ph.D.
Postdoctoral Scholar, Harvard Pilgrim Health Care Institute

Postdoctoral Advisor

Jiebing Wen, Harvard Pilgrim Health Care Institute Thomas O. Pyle Fellowship
Assistant Professor, Medical University of South Carolina College of Health Professions

Bryant Shuey, Harvard Medical School Fellowship in General Medicine and Primary Care
In progress